10-K Filing

GUIDED THERAPEUTICS INC CIK: 924515 FY 2013

Filing Information

Form Type	10-K
Accession Number	`0001121781-14-000055`
Period End Date	20131231
Filing Date	20140326
Fiscal Year	2013
Fiscal Period	FY
XBRL Instance	gthp-20131231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 76 Income Statement 40 Cash Flow Statement 63 Stockholders Equity 19

Balance Sheet 76 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$12.00K	USD	Point-in-time
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$18.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$613.00K	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$52.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.04M	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$184.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $18 and $12 at December 31, 2013 and 2012, respectively	`AccountsReceivableNet`	$133.00K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $18 and $12 at December 31, 2013 and 2012, respectively	`AccountsReceivableNet`	$107.00K	USD	Point-in-time
Series B convertible preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Inventory, net of reserves of $184 and $52 at December 31, 2013 and 2012, respectively	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$1.19M	USD	Point-in-time
Series B convertible preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Inventory, net of reserves of $184 and $52 at December 31, 2013 and 2012, respectively	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$524.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$198.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$101.00K	USD	Point-in-time
Series B convertible preferred stock, authorized	`PreferredStockSharesAuthorized`	3.00	shares	Point-in-time
Series B convertible preferred stock, authorized	`PreferredStockSharesAuthorized`	3.00	shares	Point-in-time
Series B convertible preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Series B convertible preferred stock, issued	`PreferredStockSharesIssued`	2.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$2.04M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.87M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$920.00K	USD	Point-in-time
Series B convertible preferred stock, outstanding	`PreferredStockSharesOutstanding`	2.00	shares	Point-in-time
Series B convertible preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.27M	USD	Point-in-time
Other assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$356.00K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$331.00K	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.60M	USD	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	145,000.00	shares	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	145,000.00	shares	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.28M	USD	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	62,282.00	shares	Point-in-time
TOTAL ASSETS	`Assets`	$3.48M	USD	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	70,479.00	shares	Point-in-time
TOTAL ASSETS	`Assets`	$3.32M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	62,282.00	shares	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	70,479.00	shares	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	$79.00K	USD	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	$35.00K	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	$109.00K	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	$4.00K	USD	Point-in-time
Notes payable - past due	`NotesPayablePastDue`	-	USD	Point-in-time
Notes payable - past due	`NotesPayablePastDue`	$419.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$891.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$765.00K	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$723.00K	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$1.04M	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$14.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$40.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.77M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.35M	USD	Point-in-time
Warrants, at fair value	`WarrantsNotSettleableInCashFairValueDisclosure`	$1.55M	USD	Point-in-time
Warrants, at fair value	`WarrantsNotSettleableInCashFairValueDisclosure`	-	USD	Point-in-time
Long-term debt, net	`LongtermDebtPayableLessCurrentPortion`	$103.00K	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	-	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$1.65M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$2.35M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$3.42M	USD	Point-in-time
Series B convertible preferred stock, $.001 par value; 3 shares authorized, 2 and zero shares issued and outstanding as of December 31, 2013 and 2012, respectively (liquidation preference of $ 2.1 million and 0 at December 31, 2013 and 2012, respectively)	`ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue`	$1.14M	USD	Point-in-time
Series B convertible preferred stock, $.001 par value; 3 shares authorized, 2 and zero shares issued and outstanding as of December 31, 2013 and 2012, respectively (liquidation preference of $ 2.1 million and 0 at December 31, 2013 and 2012, respectively)	`ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue`	-	USD	Point-in-time
Common stock, $.001 par value; 145,000 shares authorized, 70,479 and 62,282 shares issued and outstanding as of December 31, 2013 and 2012, respectively	`CommonStockValue`	$71.00K	USD	Point-in-time
Common stock, $.001 par value; 145,000 shares authorized, 70,479 and 62,282 shares issued and outstanding as of December 31, 2013 and 2012, respectively	`CommonStockValue`	$62.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$93.27M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$101.84M	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$132.00K	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$104.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-103.03M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-92.10M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$-107.00K	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$1.13M	USD	Point-in-time
TOTAL STOCKHOLDERS (DEFICIT) EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.13M	USD	Point-in-time
TOTAL STOCKHOLDERS (DEFICIT) EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-107.00K	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$3.48M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$3.32M	USD	Point-in-time

Income Statement 40 line items

Line Item	Tag	Value	Unit	Period
Contract and grant revenue	`Revenues`	$3.34M	USD	Annual
Contract and grant revenue	`Revenues`	$820.00K	USD	Annual
Sales - devices and disposables	`SalesDevicesAndDisposables`	$72.00K	USD	Annual
Sales - devices and disposables	`SalesDevicesAndDisposables`	$359.00K	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$117.00K	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$611.00K	USD	Annual
Gross Loss	`GrossProfit`	$-252.00K	USD	Annual
Gross Loss	`GrossProfit`	$-45.00K	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.74M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$3.23M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$424.00K	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$901.00K	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.53M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.92M	USD	Annual
Total operating expenses	`OperatingExpenses`	$7.17M	USD	Annual
Total operating expenses	`OperatingExpenses`	$7.57M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-4.28M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-6.61M	USD	Annual
OTHER INCOME	`OtherIncome`	$110.00K	USD	Annual
OTHER INCOME	`OtherIncome`	-	USD	Annual
INTEREST EXPENSE	`InterestExpense`	$72.00K	USD	Annual
INTEREST EXPENSE	`InterestExpense`	$45.00K	USD	Annual
Change in fair value of warrants	`DerivativeGainLossOnDerivativeNet`	$-674.00K	USD	Annual
Change in fair value of warrants	`DerivativeGainLossOnDerivativeNet`	-	USD	Annual
Total other income	`TotalOtherIncome`	$-72.00K	USD	Annual
Total other income	`TotalOtherIncome`	$-609.00K	USD	Annual
LOSS FROM OPERATIONS	`LossBeforeIncomeTaxes`	$4.35M	USD	Annual
LOSS FROM OPERATIONS	`LossBeforeIncomeTaxes`	$7.21M	USD	Annual
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	Annual
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	Annual
NET LOSS	`NetIncomeLoss`	$-7.21M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-4.35M	USD	Annual
PREFERRED STOCK DIVIDENDS	`PreferredStockDividendsIncomeStatementImpact`	-	USD	Annual
PREFERRED STOCK DIVIDENDS	`PreferredStockDividendsIncomeStatementImpact`	$-3.17M	USD	Annual
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-4.35M	USD	Annual
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-10.39M	USD	Annual
BASIC AND DILUTED NET LOSS PER SHARE	`EarningsPerShareBasicAndDiluted`	$-0.16	USD	Annual
BASIC AND DILUTED NET LOSS PER SHARE	`EarningsPerShareBasicAndDiluted`	$-0.08	USD	Annual
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	65,884.00	shares	Annual
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	57,429.00	shares	Annual

Cash Flow Statement 63 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-7.21M	USD	Annual
Net loss	`NetIncomeLoss`	$-4.35M	USD	Annual
Bad debt (recovery) expense	`BadDebtRecovery`	$-3.00K	USD	Annual
Bad debt (recovery) expense	`BadDebtRecovery`	$7.00K	USD	Annual
Depreciation	`DepreciationAndAmortization`	$361.00K	USD	Annual
Depreciation	`DepreciationAndAmortization`	$461.00K	USD	Annual
Stock based compensation	`ShareBasedCompensation`	$824.00K	USD	Annual
Stock based compensation	`ShareBasedCompensation`	$645.00K	USD	Annual
Change in fair value of warrants	`ChangeInFairValueOfWarrants`	-	USD	Annual
Change in fair value of warrants	`ChangeInFairValueOfWarrants`	$674.00K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-33.00K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$13.00K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$-4.00K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$-669.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$97.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-144.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$55.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-25.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-337.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$126.00K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-413.00K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-26.00K	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$223.00K	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$513.00K	USD	Annual
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$299.00K	USD	Annual
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$1.66M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-5.56M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-3.67M	USD	Annual
Additions to fixed assets	`AdditionsToNoncurrentAssets`	$-107.00K	USD	Annual
Additions to fixed assets	`AdditionsToNoncurrentAssets`	$-552.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-107.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-552.00K	USD	Annual
Net proceeds from issuance of preferred stock and warrants	`ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants`	-	USD	Annual
Net proceeds from issuance of preferred stock and warrants	`ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants`	$2.21M	USD	Annual
Proceeds from debt financing	`ProceedsFromIssuanceOfDebt`	$115.00K	USD	Annual
Proceeds from debt financing	`ProceedsFromIssuanceOfDebt`	$86.00K	USD	Annual
Payments made on notes payables	`PaymentsOfLoanCosts`	$125.00K	USD	Annual
Payments made on notes payables	`PaymentsOfLoanCosts`	$374.00K	USD	Annual
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$3.10M	USD	Annual
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$3.28M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.23M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$3.06M	USD	Annual
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-432.00K	USD	Annual
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-1.16M	USD	Annual
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$613.00K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$1.04M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`Cash`	$613.00K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`Cash`	$1.04M	USD	Point-in-time
Cash paid for Interest	`InterestPaid`	$48.00K	USD	Annual
Cash paid for Interest	`InterestPaid`	$31.00K	USD	Annual
Acquisition of minority interest	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	-	USD	Annual
Acquisition of minority interest	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$104.00K	USD	Annual
Conversion of accrued expenses into common stock	`ConversionOfAccruedExpensesIntoCommonStock`	$126.00K	USD	Annual
Conversion of accrued expenses into common stock	`ConversionOfAccruedExpensesIntoCommonStock`	$162.00K	USD	Annual
Purchase of fixed assets by issuing notes payable	`PurchaseOfFixedAssetsByIssuingNotesPayable`	$50.00K	USD	Annual
Purchase of fixed assets by issuing notes payable	`PurchaseOfFixedAssetsByIssuingNotesPayable`	-	USD	Annual
Issuance of common stock as board compensation	`IssuanceOfCommonStockAsBoardCompensation`	$463.00K	USD	Annual
Issuance of common stock as board compensation	`IssuanceOfCommonStockAsBoardCompensation`	-	USD	Annual
Deemed dividends in the form of warrants to purchase common stock.	`DeemedDividendsInFormOfWarrantsToPurchaseCommonStock.`	$537.00K	USD	Annual
Deemed dividends in the form of warrants to purchase common stock.	`DeemedDividendsInFormOfWarrantsToPurchaseCommonStock.`	$2.66M	USD	Annual
Deemed dividends on preferred stock	`DeemedDividendsOnPreferredStock`	-	USD	Annual
Deemed dividends on preferred stock	`DeemedDividendsOnPreferredStock`	$3.15M	USD	Annual

Stockholders Equity 19 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, Amount	`StockholdersEquity`	$-107.00K	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$1.13M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$1.58M	USD	Point-in-time
Issuance of Series B preferred stock, Amount	`IssuanceOfSeriesBPreferredStockAmount`	$1.34M	USD	Annual
Preferred dividends	`PreferredDividends`	$-27.00K	USD	Annual
Issuance of common stock, Amount	`IssuanceOfCommonStockAmount`	$463.00K	USD	Annual
Issuance of common stock, Amount	`IssuanceOfCommonStockAmount`	$162.00K	USD	Annual
Issuance of stock options	`IssuanceOfStockOptions`	$126.00K	USD	Annual
Exercise of warrants/options, Amount	`ExerciseOfWarrantsoptionsAmount`	$3.28M	USD	Annual
Exercise of warrants/options, Amount	`ExerciseOfWarrantsoptionsAmount`	$3.10M	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$824.00K	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$645.00K	USD	Annual
Stock-based compensation expense, Amount	`StockbasedCompensationExpenseAmount`	$824.00K	USD	Annual
Acquisition of minority interest	`AdjustmentToAdditionalPaidInCapitalAcquistionOfMinorityInterest`	$-28.00K	USD	Annual
Net Loss	`NetIncomeLoss`	$-7.21M	USD	Annual
Net Loss	`NetIncomeLoss`	$-4.35M	USD	Annual
Ending Balance, Amount	`StockholdersEquity`	$-107.00K	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$1.13M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$1.58M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.